Table 1 Demographic and Clinical Characteristics of the 246 patients, Stratified by AKI
Cohort Characteristics | AKI, No. (%) | P Value | |
|---|---|---|---|
Yes (n = 163) | No (n = 81) | ||
Age, mean (SD), y | 54.8 (9.6) | 53.2 (9.7) | 0.281 |
Female, No. (%) | 31 (19.0) | 8 (9.9) | 0.066 |
BMI, median (IQR), kg/m2 | 24.7 (22.5–27.1) | 23.0 (20.8–25.6) | 0.004 |
Personal history | |||
Smoking, No. (%) | 59 (37.1) | 29 (37.7) | 0.934 |
Alcoholism, No. (%) | 59 (37.6) | 35 (46.1) | 0.216 |
Comorbidities | |||
Hypertension, No. (%) | 44 (27.0) | 25 (30.9) | 0.527 |
Diabetes mellitus, No. (%) | 58 (35.6) | 28 (34.6) | 0.876 |
Chronic kidney disease, No. (%) | 20 (12.3) | 10 (12.3) | 0.986 |
HBV, No. (%) | 78 (47.9) | 47 (58.0) | 0.134 |
HCV, No. (%) | 6 (3.7) | 4 (4.9) | 0.641 |
Encephalopathy, No. (%) | 11 (6.7) | 6 (7.4) | 0.849 |
Ascites, No. (%) | 37 (22.7) | 18 (22.2) | 0.933 |
Underlying liver disease | 0.356 | ||
Hepatocellular carcinoma +Viral hepatitis, No. (%) | 65 (39.9) | 38 (46.9) | |
Hepatocellular carcinoma, No. (%) | 36 (22.1) | 12 (14.8) | |
Viral hepatitis, No. (%) | 32 (19.6) | 19 (23.5) | |
Alcohol-related liver disease, No. (%) | 11 (6.7) | 7 (8.6) | |
Other, No. (%) | 19 (11.7) | 5 (6.2) | |
GFR, median (IQR) | 145.0 (108.4–186.3) | 134.5 (104.0–164.3) | 0.144 |
Child-Pugh score, median (IQR) | 8.0 (7.0–9.0) | 8.0 (7.0–9.0) | 0.268 |
MELD score, median (IQR) | 6.7 (0.5–12.5) | 7.2 (2.1–14.6) | 0.474 |
Preoperative laboratory data | |||
Creatinine, median (IQR), mg/dL | 65.0 (50.0–78.0) | 71.0 (64.0–88.0) | < 0.001 |
Sodium, median (IQR), mEq/L | 140.0 (138.0–142.0) | 140.0 (137.0–142.0) | 0.865 |
Albumin, median (IQR), g/dL | 35.0 (30.6–39.7) | 35.3 (30.9–40.6) | 0.520 |
Total bilirubin, median (IQR), umol/L | 49.1 (26.6–129.3) | 44.6 (20.9–397.0) | 0.568 |
Glucose, median (IQR), mg/dL | 5.0 (4.4–6.4) | 5.2 (4.6–6.2) | 0.282 |
Lactic acid, median (IQR), mmol/L | 1.2 (1.0–1.6) | 1.3 (1.1–1.8) | 0.092 |
Surgery | |||
Estimated blood loss, median (IQR), L | 2.0 (1.0–2.5) | 1.5 (0.8–2.1) | 0.146 |
RBC transfusion, median (IQR), units | 12.0 (6.0–14.0) | 9.0 (4.0–13.5) | 0.026 |
Nadir MAP, median (IQR), mmHg | 64.9 (61.7–68.5) | 64.9 (63.3–69.3) | 0.923 |
Requirement of vasopressors (large dose), No. (%) | |||
Duration of surgery, median (IQR), min | 531.0 (468.0–572.0) | 531.0 (470.0–570.0) | 0.811 |
Cold ischemia time, median (IQR), min | 382.0 (326.0–384.0) | 383.0 (325.0–387.0) | 0.628 |
Anhepatic phase, median (IQR), min | 60.0 (52.0–60.0) | 60.0 (56.0–64.0) | 0.128 |
Postoperative parameter | |||
Peak AST, median (IQR), U/L | 526.0 (72.5–795.5) | 285.0 (79.0–742.0) | 0.805 |
Tacrolimus, median (IQR), ng/mL | 9.00 (6.65–11.50) | 8.30 (6.30–12.10) | 0.657 |
Postoperative hospitalization, median (IQR), day | 27.0 (21.0–30.0) | 25.0 (20.0–28.0) | 0.334 |
Hospital mortality, No. (%) | 5 (3.1) | 2 (2.5) | 1.000 |